Amicus Therapeutics

AMICUS THERAPEUTICS INC

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Analyst Color

Biotech

Equities

News

Downgrades

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

FOLD

IMCR

IMRX

TEVA

Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks.

Why Are Amicus, Immunocore, &amp; Immuneering Stocks Trading Lower On Friday?

Earnings

Earnings Beats

Large Cap

Mid Cap

Small Cap

Markets

ALNY

ANIP

Alnylam Pharmaceuticals (NASDAQ: ALNY) announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM).

Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU

Legality In Question

Legal

Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA approval. Litigation continues with Aurobindo.

Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug

Amicus Therapeutics Inc

Fold Holdings, Inc. - Class A Common Stock

Fold Holdings Inc

Press Releases

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024

Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates

Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook

Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025

Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025

Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law Firm

Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Alvotech

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Beam Therapeutics

Biohaven

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Denali Therapeutics

ImmunityBio

Immunovant

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

Viking Therapeutics

Wells Fargo

Cantor Fitzgerald

Morgan Stanley

JP Morgan

Comments

Amicus Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga